This most recent twist in the Lykos Therapeutics saga threatens An important overhaul of the corporate’s technique and course, with Musk ally and billionaire investor Antonio Gracias showing to choose to just take the company back again toward its nonprofit drug development roots and a more Doblinite philosophy.“I used the weekend talking a who